By using this approach, we aim to induce an immune response against pathologic alpha‐synuclein species that can have a significant protective and, potentially, also a therapeutic benefit for patients with PD, DLB, MSA, and other synucleinopathies. The gene discussed is SNCA; the disease is multiple system atrophy.